Chery rolls out Winter care campaign to support Australian drivers.

Complimentary vehicle health checks and seasonal service offers are helping Chery owners stay safe and confident on the road this winter.

SYDNEY, July 27, 2026 /PRNewswire/ -- Following another period of strong global and local growth, Chery Australia is continuing to strengthen its commitment to customer care by enhancing the ownership experience through proactive aftersales support and seasonal service initiative.

In the first half of 2026, Chery Group recorded over 943,000 overseas exports, while welcoming nearly 20 million customers worldwide. In Australia, Chery also continues to build strong momentum, delivering 24,964 vehicles during the first half of the year, representing 77 per cent year-on-year growth.

As the Chery owner community continues to expand across Australia, the company remains focused on ensuring customers enjoy confidence and peace of mind throughout every stage of vehicle ownership through its Chery Family Care customer program.

With cooler temperatures, shorter daylight hours and wetter road conditions becoming more common across Australia, winter is an ideal time for drivers to ensure their vehicles are ready for the season ahead. Chery Australia is encouraging owners to visit their nearest participating dealership, where trained technicians can help ensure your vehicle is ready for the winter season through the ongoing Chery Winter Care Campaign.

Complimentary Winter Care Campaign Now Underway

The Chery Winter Care Campaign is now running at participating Chery dealerships nationwide from 1 July to 14 August 2026.

During the campaign, eligible customers can receive:

• Complimentary Winter Vehicle Health Check
• Complimentary 12V Battery Health Check
• Complimentary Windscreen Washer Fluid Top-up
• Complimentary Brake Pad Inspection
• 50% Off Wiper Blade Rubber Refills

The campaign has been designed to provide practical seasonal support while helping customers maintain vehicle safety, reliability and confidence throughout the winter months.

Customers are encouraged to contact their nearest participating Chery dealership to confirm campaign eligibility and arrange a booking.

About Chery Family Care

Chery Family Care reflects Chery Australia's ongoing commitment to delivering professional aftersales service, trusted technical support and customer-focused care throughout every stage of vehicle ownership.

Offers are available at participating Chery dealerships during the campaign period. Eligibility, availability and terms and conditions apply.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Chery rolls out Winter care campaign to support Australian drivers.

In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH).

HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical trial evaluated the effects of fucoidan, a naturally occurring compound found in brown seaweed, on men with BPH (prostate enlargement).

BPH is a common health issue for men across the globe. Worldwide estimates place prevalence at 50-60% of men in their 60s, increasing to 90% of men in their 80s. While it is typically not life-threatening, urinary symptoms – including difficulty passing urine, a weak stream and an increase in the frequency of urination – often result in a significant reduction in quality-of-life.

Speaking of the rationale behind the study, lead researcher Dr Barbara Wimmer said, "To date, very few natural compounds have been clinically studied and shown to support prostate health effectively. The documented bioactivities of fucoidan led us to embark on this groundbreaking trial."

In the 90-day study overseen by clinicians, 88 men aged between 45 and 80 years with moderate BPH received either a daily fucoidan supplement or a placebo.

Key findings
Compared to the placebo, participants taking the high purity fucoidan supplement showed:

• Clinically significant improvements in overall BPH symptoms
• A more than nine-fold improvement in voiding symptoms (encompassing the symptoms of emptying, intermittency, weak stream and straining)
• A two-fold improvement in storage symptoms (encompassing the symptoms of frequency, urgency and nocturia)
• A significant improvement in quality-of-life due to urinary symptoms

Watch the clinical trial overview and learn more about the findings.

The study utilised the widely recognised International Prostate Symptom Score (IPSS) to assess changes in BPH symptoms.

Dr Wimmer explained, "Importantly, the trial results were clinically significant and the fucoidan was shown to be safe throughout the study period. We expect these findings will result in the commercialisation of high purity fucoidan to help relieve the symptoms of benign prostatic hyperplasia."

The study was published in the journal Research and Reports in Urology.  

About Marinova          

Marinova is an Australian biotechnology company specialising in the research, development and manufacture of high purity fucoidans for inclusion in nutritional, medical device, skincare and pharmaceutical applications. 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Seaweed extract shown to relieve prostate symptoms